Venice Film Festival: The Web Series Artitude Created by Pomilio Blumm Receives an Award for Promoting the Made in Italy Brand

Lorenzo Balbi at the Venice Film Festival

The Social World Film Festival jury’s special plaque for the project created by Pomilio Blumm was received by Lorenzo Balbi, director of MAMbo (Museum of Modern Art in Bologna), artistic director of ArtCity as well as a narrator in the various episodes of the series.

VENICE, Italy, Sept. 12, 2022 (GLOBE NEWSWIRE) — The prize awarded to the web series Artitude was presented in Venice as part of the Film Festival. The Social World Film Festival jury’s special plaque for the project created by Pomilio Blumm was received by Lorenzo Balbi, director of MAMbo (Museum of Modern Art in Bologna), artistic director of ArtCity as well as a narrator in the various episodes of the series. Artitude was created by Pomilio Blumm as part of Italy is simply extraordinary: beIT–  the campaign aimed at promoting Italian-made products launched by the Ministry of Foreign Affairs and International Cooperation, in collaboration with ICE – Agency for the promotion abroad and internationalisation of Italian companies. As Lorenzo Balbi himself explained: “The campaign explored Made in Italy and did it through different languages, those of art, creativity, the languages of knowledge. A way of talking about Italy through artists, creatives, visionaries.”

The project was also awarded during the WMF 2022 – the largest Digital Innovation Festival in Rimini, where it won the Best International Content & Digital Campaign– an acknowledgement received for the innovation of the narrative and strategic structure adopted with respect to the objective of the Nation branding and promotion of Made in Italy.

From the outset, the campaign curated by Pomilio Blumm set for itself ambitious goals: to tell the international public about the values of Italy and its talents, to support the internationalisation of the production system, and finally to expand and diversify the foreign markets of reference for small and medium-sized Italian companies. The campaign began by telling the Made in Italy story through six very specific values: creativity, passion, tradition, innovation, style and diversity. Personalities of the stature of Giorgio Armani, Mira Sorvino, Peter Gabriel, Marcell Jacobs, Sebastião Salgado, Renzo Rosso and many others have offered their testimonials in support of this project– all of them can be found on the Nation Branding Flagship Sitemadeinitaly.gov.it

For more information:
LaPresse SpA Communication and Press Office Director
Barbara Sanicola – barbara.sanicola@lapresse.it

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0e2890a5-2c72-40d5-adc3-b74128295580

The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.

Mecobit Mining Rigs Announces the Biggest Hash-Rate in the Market

LONDON, Sept. 12, 2022 (GLOBE NEWSWIRE) — MECO Limited (Mecobit), one of the world’s leading manufacturers of solar modules and complete solutions, recently launched new products Solar Unit M4000, Solar Panel Kit (complete), Portable Power Station, M100 Miner, M200 Miner, Meco Rack, which has attracted wide attention in the industry. The result of five years of research, development and testing, this new technology platform enables the production of frameless, thin, lightweight and adaptable solar panels with the performance of comparable standard solar panels.

“We are very excited to bring revolutionary innovation to the field of solar energy,” said Ben Lukas (Chief Marketing Officer). “In addition to the new development work and modules from design and material, this new technology platform has fundamentally helped us with the unique solar-electric technology. Mecobit The Solar System has a unique ability to pass through the shadow, continuing to produce energy in conditions that will shut down other panels.”

Compared to previous innovations, charging speed, battery life, security guarantees and user experience have improved. Mecobit M4000 Solar Unit and Solar Panel Kit is compatible with many devices, tools, equipment, home and electronic industries such as cryptocurrency miners, providing security, long backup and other areas of power. Mecobit Solar Systems Long Life Battery: M4000 Solar Unit, Solar Panel Kit (complete), Portable Power Station passes standard tests such as short circuit, overload, extrusion, acupuncture, etc.

And as governments agree to reduce levels of carbon emissions and introduce additional incentives like investment tax credits, it’s possible that the share of mining operations using solar power will increase even more. Solar power may be considered green and renewable, but there are also significant problems with solar, including the limits of sunlight hours.

Shipping costs

As a consequence of this, Mecobit will pay for both shipping and import tariffs, enabling customers to acquire everything they require to get started with no further costs beyond the cost of the device itself.

About Mecobit

Established in 2015 with the goal of developing and marketing the world’s solar powered cryptocurrency miners, which can use either Ethash, SHA-256 or Scrypt technology depending on the miner’s preference. The company asserts that it was the very first solar powered cryptocurrency mining enterprise in the world. “We wanted to revolutionize the industry with the solar panels by providing more power at a more affordable price than was previously thought to be possible,” B. Franci (Founder).

Mecobit is headquartered in Chiswick High Road, London, England, and has offices in several other cities across the world, including the United States. The company’s website, www.mecobit.com, provides additional information on the company and its products.

Ben Lukas
ben.lukas@mecobit.com

Neeyamo’s Global Screening Services is Now ScreenXchange – an Independent Business Unit Poised for Tremendous Growth

ScreenXchange provides a superior screening experience courtesy of its peerless delivery model.

LOS GATOS, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) — Success in a rapidly evolving borderless business environment requires bleeding-edge employee screening to ensure you have the right talent with validated credentials that mitigates organizations from potential risks. Neeyamo is elated to announce the launch of ScreenXchange, a rebranded independent global offering for background screening that supports client requirements in over 190+ countries.

ScreenXchange provides a superior screening experience courtesy of its peerless delivery model. Its tech-driven solution hosts its native screening solution suite that covers 27 background checks and includes a multi-sided marketplace of vetted global screening partners that can collectively provide its clients with cross-border screening options.

Comprehensive compliance is at the heart of our unmatched service delivery that caters to various employment screening needs across all industries. Our integration-ready platform connects to major applicant tracking system (ATS) providers, ensures seamless data flow, eliminates silos, and accelerates the hiring cycle.

ScreenXchange will leverage over a decade of the organization’s experience in the background screening industry, which began in 2010 by introducing a single platform that linked all key stakeholders providing faster turnaround and increased accuracy.

With a built-in quality control mechanism, superior applicant experience, and a proprietary global platform, it aims to create a smarter, more straightforward, seamless screening process that addresses the needs of all parties in the marketplace.

Speaking on the sidelines of the global unveiling at PBSA 2022, Rangarajan Seshadri, CEO of Neeyamo, said, “As a technology-first background screening platform, ScreenXchange aims to weaponize data analysis. By leveraging AI and machine learning, risk and threat analysis can be done more quicker, resulting in reduced TAT. End-to-end automation harmonizes data collection and provides enhanced data security. Our commitment to reducing manual intervention and proclivity for innovative solutions to create a smarter screening process remains unwavering.”

About ScreenXchange

ScreenXchange is a leading background screening provider for organizations of all sizes. Our technology-first solution caters to a wide range of employment screening needs in 190+ countries. With compliance at its nerve center, it is designed to accelerate your hiring cycle, optimize your screening process, and promote quality hires. To know more, visit www.screenxchange.com.

Media Contact: corporate.communications@neeyamo.com

This content was issued through the press release distribution service at Newswire.com.

Truth and justice: A conversation with the families of Flight PS752 victims

WASHINGTON, Sept. 12, 2022 (GLOBE NEWSWIRE) —

When:
1:00 p.m. ET on Wednesday, September 14, 2022

Where:
1030 15th Street, NW, 12th Floor
Washington, DC 20005

Registration and virtual attendance available via the link below:
https://www.atlanticcouncil.org/event/truth-and-justice-a-conversation-with-the-families-of-flight-ps752-victims/

What:
The Association of Families of Flight PS752 Victims (the Association) will be participating in a discussion hosted by the Atlantic Council’s Strategic Litigation Project about the lasting impact of the downing of Flight PS752 and legal options for accountability.

The conversation will feature several representatives of the Association and legal experts to discuss the path toward redress for the victims and their families. This marks the first time family members of the victims will be gathered in-person in Washington, D.C. to make their demands heard.

This discussion will be held both in-person and via Zoom. The event is open to press and on-the-record.

Who: Representatives from the Association will include:

  • Amirali Alavi – Director & Chair, Legal Committee
  • Kourosh Doustshenas – Director & Chair, Government and Stakeholder Relations Committee
  • Navaz Ebrahim – Director & Chair, Public Relations Committee
  • Dr. Hamed Esmaeilion – President & Spokesperson
  • Javad Soleimani – Chair, Fact-Finding Committee
  • Ashkan Davoudpour – Member, Fact-finding Committee
  • Alborz Sadeghi – Member, Legal Committee

Legal experts will include:

  • Haydee Dijkstal – Barrister, 33 Bedford Row
  • Gissou Nia – Director, Strategic Litigation Project, Atlantic Council

Moderated by:

  • Joyce Karam – Senior Correspondent, The National

For more information contact:

Oliveah Numan
onuman@sussex-strategy.com

Gissou Nia
gnia@atlanticcouncil.org

Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

VANCOUVER, British Columbia, Sept. 12, 2022 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has received approval to conduct a Phase 1 clinical study of an intravenous formulation (“IVF”) of AP-188 (“N,N-dimethyl tryptamine” or “DMT”) for the treatment of stroke in the Netherlands from the Stichting Beoordeling Ethiek Biomedisch Onderzoek (“BEBO”), an independent Medical Research Ethics Committee (“MREC”). The trial will be conducted at the Centre for Human Drug Research (“CHDR”) in Leiden. DMT is a known psychedelic compound that is part of the tryptamine family.

The Company plans to begin screening shortly and dose the first subject of the study in Q4, 2022.

The Company’s decision to investigate DMT and move it into human trials for ischemic stroke is based on multiple independent, positive preclinical studies demonstrating that DMT helps mitigate tissue damage and promote neurogenesis as well as structural and functional neural plasticity. These are key factors involved in the brain’s ability to form and reorganize synaptic connections, which are needed for healing following a brain injury. The Company also confirmed in its own murine cortical neuron outgrowth preclinical study, that DMT, in sub-psychedelic doses, increased the growth of cortical neurons by up to 40% compared to control.

Since there have already been several Phase 1 studies successfully conducted on DMT, the Company is not anticipating any serious adverse events or safety issues arising from its study. The reason that the Company is planning to conduct a Phase 1 study and not directly advance DMT into a Phase 2 study is that it is investigating prolonged intravenous infusion of DMT, for durations which have never been clinically studied. The resulting data generated will help the Company to plan both its Phase 2 acute stroke and rehabilitation studies more effectively.

“I was drawn to DMT’s endogenous nature and possible role in naturally occurring altered states of consciousness such as dreams and psychosis, as well as being a prototype for other psychedelic drugs in common use,” said Algernon consultant Rick Strassman MD, psychiatrist and psychopharmacologist, and author of the best-selling book DMT: The Spirit Molecule. Strassman’s NIH-funded Phase 1 study of DMT, which ran from 1990-1995 at the University of New Mexico, was the first new American clinical research with psychedelic drugs in a generation. The study assessed biological and psychological effects in normal volunteers and demonstrated that studies of psychedelics could be done safely in humans. He continued “Our careful assessment of psychedelic and non-psychedelic doses of DMT established guidelines for studies utilizing its neuroplastogenic effects in stroke, an application I would not have predicted at the time. These more recent findings of DMT’s effects have opened an extraordinarily promising set of potential therapeutic applications for Algernon to explore.”

Dr. David Nutt, Professor of Neuropsychopharmacology at Imperial College London, also an Algernon consultant, said, “I am pleased to see Algernon moving forward with the CHDR, with whom I have worked in the past and respect greatly,” said. “Although the study is in healthy volunteers, the protocol includes study of some markers which may give some early clues about potential benefits in stroke victims.”

Christopher J. Moreau CEO of Algernon Pharmaceuticals further commented saying, “We look forward to getting our DMT clinical stroke program started with our Phase 1 study at CHDR in the Netherlands,” said. “This study will provide important information on dosage and duration of our new DMT IVF formula to help us better plan for our Phase 2 where we plan to test the drug with both acute and recovering stroke patients.”

Phase 1 DMT Stroke Study Summary

The purpose of the study is to identify the safety, tolerability, and pharmacokinetics of DMT when administered as an intravenous bolus followed by prolonged infusion, for durations which have never been studied clinically. In addition, several pharmacodynamic measures believed to be associated with neuroplasticity, including both measurements of biochemical markers and electroencephalographic readings, will be recorded.

The first part of the study will use a single-escalating dose design aimed at identifying a safe and tolerable dose that will not produce psychedelic effects, while the second part will test the effects of repeated administrations of this dose. There will be up to 60 healthy volunteers enrolled across the two parts of the study which will include both psychedelic experienced and psychedelic naïve patients.

About CHDR

Founded in 1986, the CHDR is an independent institute that specializes in cutting-edge early-phase clinical drug research. During the pandemic of 2021 the CHDR completed renovations to greatly increase their clinical capacity while also being responsible for 77 scientific publications.

CHDR’s custom-built facility is situated in the heart of the Leiden Bio Science Park within Leiden University (LUMC) campus adjacent to the medical school and GMP pharmacy. CHDR’s long-standing partnership with the LUMC facilitates direct access to an extensive knowledge base in Leiden, as well as access to different patient populations for trial recruitment. This partnership as well as the combined expertise of two board certified neurologists and post-doctorate clinical scientists with neuroscientific backgrounds will be valuable assets as Algernon’s DMT program moves forward. In addition, they have performed multiple clinical trials with psychedelic substances, including DMT, and have a suite of rooms specifically created for that purpose.

The Company had initially retained the CHDR and its affiliated pharmacy at the Leiden University Medical Center in the Netherlands, to develop the IVF that will be used in its Phase 1 DMT study. After working with the CHDR team, it was decided to move forward with an ethics and clinical trial application in Netherlands as well to move Algernon’s DMT stroke research program forward as quickly as possible.

About DMT

N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. DMT occurs naturally in many plant species and animals including humans and has been used in religious ceremonies as a traditional spiritual medicine by indigenous people in the Amazonian basin. DMT can also be synthesised in a laboratory.

Algernon has filed patents for DMT pamoate and nicotinate (novel salt forms of DMT) in addition to formulation, dosage and method of use claims for ischemic stroke. The Company has also filed claims for combination therapy of DMT and stroke rehabilitation including Constraint Induced Movement Therapy.

About Algernon Pharmaceuticals Inc. 

Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

CONTACT INFORMATION

Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701

info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

☀️ Morning digest September 12

– Members of the Party Central Committee’s Politburo and Secretariat gave opinions on a number of projects during their meeting on September 9-10 under the chair of Party General Secretary Nguyen Phu Trong. The projects include those on building and perfecting the rule-of-law socialist State of Vietnam in the new period; stepping up the national industrialisation and modernisation until 2030 with a vision to 2045; reviewing the 10-year implementation of the Politburo’s Resolution 10 dated January 18, 2002 on promoting socio-economic development and ensuring national defence and security in the Central Highlands and Conclusion 12 dated October 24, 2011 on the continued implementation of Resolution 10. Read full story

– Prime Minister Pham Minh Chinh requested that the Vietnam Oil and Gas Group (PetroVietnam) ensure energy sufficiency during a working session on September 11 to seek ways for accelerating some key projects and solving difficulties facing the firm.

PetroVietnam General Director Le Manh Hung said the group has continued affirming its role in Vietnam’s economy by helping guarantee the national energy, food, economic, and sovereignty security and contributing to the State budget.Read full story

– An official visit to Vietnam from September 12 to 14 by President of the Cambodian National Assembly Samdech Heng Samrin is an important political and diplomatic event in the Vietnam – Cambodia Friendship Year 2022 and amid the 55th anniversary of the diplomatic relationship (June 24). After Vietnam and Cambodia set up diplomatic ties on June 24, 1967, their peoples stood side by side in the struggles for national liberation to secure historic victories in the spring of 1975. Vietnam later assisted the patriotic forces and people of Cambodia to topple the Pol Pot genocidal regime, with the triumph on January 7, 1979. Read full story

– Foreign Minister Bui Thanh Son on September 10 came to the residence of UK Ambassador to Vietnam Gareth Ward to extend his condolences over the passing away of Queen Elizabeth II. Writing in the condolence book, Son stressed his respect for the Queen’s fine sentiments towards Vietnam and her support for fostering the cooperative ties between the two nations. He extended his deepest condolences to the Royal Family, government and people of the UK. Read full story

– Deputy Minister of Environment and Natural Resources Le Cong Thanh held talks with Cuban Deputy Minister of Science, Technology and Environment Adianez Taboada during his visit to Cuba from September 5–9. The visit aimed to boost cooperation in hydrometeorology, environment and circular economy between the two countries. Read full story

– A delegation of the Ministry of Planning and Investment paid a visit to Israel from September 4 to 9 to learn experience in developing the collective economy and cooperatives there. The delegation was led by Director of the ministry’s Agency for Cooperative Development Phung Quoc Chi, who is also head of the compilation group for the draft revised Law on Cooperatives. Some members of the compilation group from the National Assembly Office and the ministry also joined the delegation. Read full story

– Vietnam has become the most favourite destination in Southeast Asia among Cambodian travellers since the beginning of 2022, Cambodian-based electronic news outlet Thmeythmey reported on September 10. Cambodian tourist arrivals to Vietnam in the first eight months of 2022 tripled figure in the same period of 2019 recorded before the outset of the COVID-19 pandemic, the news site said.Read full story

– A 600-sqm memorial house where remains of Vietnamese volunteer soldiers dying in battle in Cambodia will be kept was inaugurated in the north-western province of Battambang on September 10. Starting two months ago, the facility’s construction was funded by Metfone, the Cambodia-based affiliate of military-run telecom group Viettel, and MB Bank in Cambodia. Read full story/.

Source: Vietnam News Agency

President of Cambodian NA pays official visit to Vietnam

 President of the Cambodian National Assembly (NA) Samdech Heng Samrin is paying an official visit to Vietnam from September 12 to 14 at the invitation of NA Chairman Vuong Dinh Hue.

This is an important political and diplomatic activity between the two legislatures in the Vietnam – Cambodia Friendship Year 2022 and in celebration of the 55th founding anniversary of diplomatic relations between the two nations (June 24).

The Cambodian delegation also includes Men Sam An, Deputy Prime Minister, Minister of the NA – Senate Relations and Inspection, and Chairwoman of the Cambodia – Vietnam Parliamentary Friendship Group; Chheang Vun, Chairman of the NA’s Commission on Economy, Finance, Banking and Auditing and Vice Chairman of the Cambodia – Vietnam Parliamentary Friendship Group; Loy Sophat, Chairman of the NA’s Commission on Planning, Investment, Agriculture, Rural Development, Environment, and Water Resources; Suos Yara, Chairman of the NA’s Commission on Foreign Affairs, International Cooperation, Propaganda, and Information; and Cambodian Ambassador to Vietnam Chay Navuth, among others.

Samdech Heng Samrin is also Chairman of the National Council of the Solidarity Front for the Development of Cambodian Motherland and Honorary President of the Cambodian People’s Party./.

Source: Vietnam News Agency

Short film calls for report on wildlife violations

 Education for Nature – Vietnam (ENV) has released a short film calling for the community to report violations of wildlife protection provisions to its free hotline 1800-1522.

The film, the second the ENV has made this year, has been aired on 50 central and local television channels. It illustrates how the organisation handles a violation report received via the hotline. ENV Vice Director Nguyen Thi Phuong Dung said that the community is the key force in wildlife protection efforts in each locality. By just one call, each people can contribute to preventing violations and protecting the wildlife, she stressed.

According to Dung, since the hotline was put into use in 2005, it has received more than 24,000 reports of wildlife violations, helping authorities to seize tonnes of wild animals and products.

Each day, the ENV gets about 10 reports from the community via the hotline. Last year, thanks to the reports, nearly 1,000 wild animals that were illegally caged and traded were rescued, she added./.

Source: Vietnam News Agency